Why “we’re safe” is the most dangerous assumption in medical benefit commercialization.
|Articles|April 11, 2023
What Can Pharma Do for Patients Post IRA?
Kevin Hagan, president and CEO of the PAN Foundation, discusses how pharma can help Medicare patients post-IRA reform.
Advertisement
Kevin Hagan, president and CEO of the PAN Foundation, discusses how pharma can help Medicare patients post-IRA reform. Hagan notes there is a continuing need to have copay assistance because Medicare patients still face a $2K out of pocket cost, which is still a challenge for many of them.
Visit the PAN Foundation's "
Advertisement
Related to this article
Incubate’s John Stanford on why MFN hits mid-sized pharma harder — fewer products to absorb margin hits and less access to cheap capital.
Improved financing conditions and accelerating M&A are creating new opportunities, but policy uncertainty, patent expirations and persistent funding pressures continue to shape the outlook for pharma and biotech.
Advertisement
Advertisement
Trending on PharmExec
1
EMA Panel Backs Lilly’s Foundayo for Obesity and Type 2 Diabetes in Europe
2
FDA Approves Enspryng (Satralizumab) for Thyroid Eye Disease
3
The Bubble You Don’t Know You’re In: A Three-Part Series on The Medical Benefit Bubble
4
Domestic Manufacturing Is a Meaningful But Incomplete Answer
5